GSK To Gain Fluviral Vaccine Through Acquisition Of ID Biomedical
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline plans to acquire ID Biomedical for $1.4 bil., a deal that could provide GSK with a second flu vaccine in the U.S. for the 2006/2007 flu season.